FY2027 EPS Estimates for TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Reduced by Analyst

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) – Equities researchers at Roth Capital cut their FY2027 earnings per share estimates for TFF Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.03 for the year, down from their previous estimate of $2.28. The consensus estimate for TFF Pharmaceuticals’ current full-year earnings is ($6.51) per share.

Separately, Roth Mkm cut their price target on TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, March 28th.

TFF Pharmaceuticals Price Performance

Shares of TFFP stock opened at $2.16 on Thursday. TFF Pharmaceuticals has a 52-week low of $1.54 and a 52-week high of $16.94. The company’s 50 day moving average is $4.45 and its 200 day moving average is $6.00.

TFF Pharmaceuticals (NASDAQ:TFFP) last posted its earnings results on Thursday, March 28th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.01). TFF Pharmaceuticals had a negative net margin of 2,251.52% and a negative return on equity of 195.14%. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.20 million.

Institutional Trading of TFF Pharmaceuticals

Several hedge funds have recently modified their holdings of TFFP. AIGH Capital Management LLC raised its stake in shares of TFF Pharmaceuticals by 70.7% during the 3rd quarter. AIGH Capital Management LLC now owns 2,655,235 shares of the company’s stock worth $929,000 after acquiring an additional 1,099,709 shares in the last quarter. Worth Venture Partners LLC grew its holdings in TFF Pharmaceuticals by 66.2% in the third quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock worth $226,000 after purchasing an additional 257,722 shares during the last quarter. Finally, Westside Investment Management Inc. increased its position in shares of TFF Pharmaceuticals by 382.1% during the first quarter. Westside Investment Management Inc. now owns 39,225 shares of the company’s stock worth $237,000 after purchasing an additional 31,089 shares in the last quarter. 15.25% of the stock is owned by hedge funds and other institutional investors.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.